Investigational drugs for hyperuricemia, an update on recent developments

References

• Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82(3):141–143.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301–1311.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.
   PubMed Web of Science ®Google Scholar
• Hui M, Carr A, Cameron S, et al. The British society for rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017;56:1056–1059.
   Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. Japanese society of G, nucleic acid M. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018–1029.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–3141.
   PubMed Web of Science ®Google Scholar
• Pascart T, Liote F. Gout: state of the art after a decade of developments. Rheumatology (Oxford). 2018 Mar 13. doi: 10.1093/rheumatology/key002.
   PubMedGoogle Scholar
• Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76:811–820.
   Web of Science ®Google Scholar
• Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheum. 2017;69(1):203–212.
   PubMed Web of Science ®Google Scholar
• Pascart T, Richette P. Current and future therapies for gout. Expert Opin Pharmacother. 2017;18(12):1201–1211.
   PubMed Web of Science ®Google Scholar
• Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014;10(10):CD006077.
   Google Scholar
• Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–2164.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704–709.
   PubMed Web of Science ®Google Scholar
• Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: the LASSO study. Semin Arthritis Rheum. 2015;45(2):174–183.
   PubMed Web of Science ®Google Scholar
• Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015;17:120.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Barclay M, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis. 2017;76(12):2065–2070.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522–1528.
   PubMed Web of Science ®Google Scholar
• Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017;84(5):595–598.
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr., Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548.
   PubMed Web of Science ®Google Scholar
• Merriman TR. An update on the genetic architecture of hyperuricemia and gout. Arthritis Res Ther. 2015;17:98.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Torok M, Hanni A, et al. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005;41(4):925–935.
   PubMed Web of Science ®Google Scholar
• Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014(11):CD010457.
   Google Scholar
• Stamp LK, Haslett J, Frampton C, et al. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. Intern Med J. 2016;46(9):1075–1080.
   PubMed Web of Science ®Google Scholar
• Baraf HS, Becker MA, Gutierrez-Urena SR, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15(5):R137.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Jama. 2011;306(7):711–720.
   PubMed Web of Science ®Google Scholar
• Becker MA, Baraf HS, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72(9):1469–1474.
   PubMed Web of Science ®Google Scholar
• Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56(12):2170–2178.
   PubMed Web of Science ®Google Scholar
• Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. Bmj. 2013;347:f4262.
   PubMed Web of Science ®Google Scholar
• Li X, Meng X, Timofeeva M, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. Bmj. 2017;357:j2376.
   PubMed Web of Science ®Google Scholar
• Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161–2167.
   PubMed Web of Science ®Google Scholar
• Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148–1156.
   PubMed Web of Science ®Google Scholar
• Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763–1771.
   PubMed Web of Science ®Google Scholar
• Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58.
   PubMed Web of Science ®Google Scholar
• Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. 2017;10:CD009460.
   PubMedGoogle Scholar
• Beddhu S, Filipowicz R, Wang B, et al. A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis. 2016;3:2054358116675343.
   Google Scholar
• Richette P, Perez-Ruiz F, Doherty M, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654–661.
   PubMed Web of Science ®Google Scholar
• Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford). 2018;57(suppl_1):i47–i50.
   PubMedGoogle Scholar
• Bove M, Cicero AFG, Borghi C. The effect of xanthine oxidase inhibitors on blood pressure and renal function. Curr Hypertens Rep. 2017;19(12):95.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Ogawa Y, Hashimoto H, et al. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther. 2016;41(3):290–297.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Ohno I, Nomura S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18(6):876–884.
   PubMed Web of Science ®Google Scholar
• Mizukoshi T, Kato S, Ando M, et al. Renoprotective effects of topiroxostat for hyperuremic patients with overt diabetic nephropathy study (ETUDE Study): A prospective, randomized, multicenter clinical trial. Nephrology (Carlton). 2017 Oct 9. doi: 10.1111/nep.13177.
   PubMedGoogle Scholar
• Wada T, Hosoya T, Honda D, et al. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clin Exp Nephrol. 2018 Jan 25. doi: 10.1007/s10157-018-1530-1.
   Google Scholar
• Hollister AS, Maetzel A, Becker MA, et al. Ulodesine (BCX4208) long-term safety when added to allopurinol in the chronic management of gout: a phase 2 24-week blinded safety extension and vaccine challenge study. Arthritis Rheum. 2012;64(10 Suppl):S1–1216.
   PubMedGoogle Scholar
• Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012;8(10):610–621.
   PubMed Web of Science ®Google Scholar
• Nakayama A, Nakaoka H, Yamamoto K, et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis. 2017;76(5):869–877.
   PubMed Web of Science ®Google Scholar
• Tan PK, Liu S, Gunic E, et al. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017;7(1):665.
   PubMed Web of Science ®Google Scholar
• Shen Z, Gillen M, Miner JN, et al. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Des Devel Ther. 2017;11:2077–2086.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Winkle P, Miner JN, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 2018;4(1):e000584.
   PubMed Web of Science ®Google Scholar
• Tan PK, Ostertag TM, Miner JN. Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep. 2016;6:34995.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Sugeno M, Liu S, et al. Pharmacokinetics, and safety of verinurad in combination with febuxostat versus febuxostat alone and verinurad alone in Japanese adults with gout or asymptomatic hyperuricemia: a phase 2a, open-label study [abstract]. Arthritis Rheum. 2016;68(Suppl 10):1–4550.
   Google Scholar
• Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017;15(1):158.
   PubMedGoogle Scholar
• Poiley J, Steinberg AS, Choi YJ, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheum. 2016;68(8):2027–2034.
   PubMed Web of Science ®Google Scholar
• Steinberg AS, Vince BD, Choi YJ, et al. pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout. J Rheumatol. 2017;44:374–379.
   PubMed Web of Science ®Google Scholar
• Ahn SO, Ohtomo S, Kiyokawa J, et al. Stronger uricosuric effects of the novel selective urat1 inhibitor ur-1102 lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbromarone. J Pharmacol Exp Ther. 2016;357(1):157–166.
   PubMed Web of Science ®Google Scholar
• Lee HA, Park SI, Yoon S, et al. A pharmacokinetic and pharmacodynamic evaluation of urc102, a potent and selective inhibitor of urat1, after single and multiple oral administrations in healthy volunteers [abstract]. Arthritis Rheum. 2017;69(Suppl 10):1–4426.
   Google Scholar
• Mandal AK, Mercado A, Foster A, et al. Uricosuric targets of tranilast. Pharmacol Res Perspect. 2017;5(2):e00291.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Kitt MM, Griffith SG, et al. The combination of tranilast with allopurinol results in enhanced urate lowering [abstract]. Arthritis Rheum. 2010;62(Suppl 10):1.
   Google Scholar
• Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953–1961.
   PubMed Web of Science ®Google Scholar
• Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338–10342.
   PubMed Web of Science ®Google Scholar
• Matsuo H, Takada T, Nakayama A, et al. ABCG2 dysfunction increases the risk of renal overload hyperuricemia. Nucleosides Nucleotides Nucleic Acids. 2014;33(4–6):266–274.
   PubMed Web of Science ®Google Scholar
• Miyata H, Takada T, Toyoda Y, et al. Identification of febuxostat as a new strong abcg2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol. 2016;7:518.
   PubMed Web of Science ®Google Scholar
• International Transporter C, Giacomini KM, Huang SM, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014;111(10):3763–3768.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60.
   PubMed Web of Science ®Google Scholar
• Allen KC, Champlain AH, Cotliar JA, et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 2015;38(2):183–187.
   PubMed Web of Science ®Google Scholar
• Nyborg AC, Ward C, Zacco A, et al. A therapeutic uricase with reduced immunogenicity risk and improved development properties. PLoS One. 2016;11(12):e0167935.
   PubMed Web of Science ®Google Scholar
• Sands E, Kivitz AJ, DeHaan W, et al. 2 clinical data of SEL-212 in symptomatic gout patients: monthly dosing of a pegylated uricase (pegsiticase) with svp-rapamycin enables sustained reduction of serum uric acid levels by mitigating formation of anti-drug antibodies [abstract]. Arthritis Rheum. 2017;69(Suppl 10):1–4426.
   Google Scholar
• Warrell RP, Klukovits A, Barnes K, et al. Profound hypouricemia induced in human subjects by novel bifunctional inhibitors of xanthine oxidase and URAT1 [abstract]. Arthritis Rheum. 2014;66(Suppl 10):S1–S1402.
   Google Scholar
• Dua P, Gurrell R, Kirby S, et al. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. Clin Rheumatol. 2016;35(8):2045–2051.
   PubMed Web of Science ®Google Scholar
• Noveck RJ, Wang Z, Forsthoefel A, et al. Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S1–1216.
   PubMedGoogle Scholar
• Kubomura D, Yamada M, Masui A. Tuna extract reduces serum uric acid in gout-free subjects with insignificantly high serum uric acid: a randomized controlled trial. Biomed Rep. 2016;5(2):254–258.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Stamp LK. Gout: why compare the effectiveness of suboptimal gout management? Nat Rev Rheumatol. 2015;11(9):506–507.
   PubMed Web of Science ®Google Scholar
• Abhishek A, Jenkins W, La-Crette J, et al. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study. Rheumatology (Oxford). 2017;56(4): 529–533.
   PubMed Web of Science ®Google Scholar
• Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(3):547–551.
   PubMed Web of Science ®Google Scholar
• Latourte A, Soumare A, Bardin T, et al. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis. 2017.
   Web of Science ®Google Scholar